FDA Approves Oral Treatment for CSU

Remibrutinib is the first Bruton tyrosine kinase inhibitor approved by the FDA for chronic spontaneous urticaria.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/fda-approves-oral-btk-inhibitor-chronic-spontaneous-2025a1000q9c?src=rss

Author :

Publish date : 2025-10-01 07:09:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

FDA Approves Oral Treatment for CSU

How Do Cancer Survivors Fare After Lung Cancer Screening?

Ultraprocessed Foods Strongly Linked to Elevated MS Activity

Related Posts

Early Vaccination May Have Mitigated Texas Measles Outbreak

Low-Fat Vegan Diet Cuts Insulin Use and Costs in T1D

Life Medicine Program Helps T2D Patients at Risk for CKD

Which Diagnostic Steps Help Spot Sjögren Syndrome Early?

The Patient Portal That Patients Can’t Navigate

Can Anticoagulants Cut Stroke Risk in Seniors With AF?

Early Vaccination May Have Mitigated Texas Measles Outbreak

Low-Fat Vegan Diet Cuts Insulin Use and Costs in T1D

Life Medicine Program Helps T2D Patients at Risk for CKD

Which Diagnostic Steps Help Spot Sjögren Syndrome Early?

The Patient Portal That Patients Can’t Navigate

Can Anticoagulants Cut Stroke Risk in Seniors With AF?

Cognition Improved With Some Drugs for Depression

Why Do Caregivers Delay Early Allergenic Food Introduction?

Categories

Archives